It was reported previously that monoclonal antibodies that target PCSK9 (such as evolocumab and alirocumab) can alleviate vascular events, including stroke (Castilla-Guerra, Fernandez-Moreno & Rico-Corral, 2019). The gene discussed is PCSK9; the disease is Stroke.